The U.S. Food and Drug Administration has approved Jobevne (bevacizumab-nwgd), a biosimilar to Avastin (bevacizumab) for ...

FDA approves Biocon Biologics' Jobevne, a biosimilar Bevacizumab for cancer treatment, expanding access to affordable ...

Biocon’s share price rose 5.5% after USFDA approved JOBEVNE, a biosimilar cancer drug. This marks the company’s seventh USFDA ...

The US Food and Drug Administration (FDA) has approved bevacizumab-nwgd (Jobevne, Biocon Biologics Ltd), a biosimilar to bevacizumab (Avastin, Genentech), for intravenous use across multiple cancer ...

Biocon Biologics, the biosimilar arm of Biocon has expanded its oncology portfolio with the USFDA approval of Jobevne, a ...

Biocon Biologics' Jobevne, a biosimilar of Avastin, approved by the FDA, expanding oncology portfolio and access to ...

Biocon Biologics Limited (BBL) announced on Thursday that it had received approval from the United States Food and Drug ...

Biocon Biologics receives USFDA approval for Jobevne (bevacizumab-nwgd), a biosimilar Bevacizumab for treating various ...

Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), today announced that the U.S. Food and Drug Administration (U.S. FDA) has approved Jobevne™ (bevacizumab-nwgd), ...

The US sales of bevacizumab were around $2 billion in 2023. Amgen, Amneal, Celltrion and Pfizer are its competitors in the US ...

In 2023, bevacizumab sales in the U.S. were around $2.0 billion. Biocon Biologics serves over 5 million patients each year ...